Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Swedish Orphan Biovitrum Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 1/6

Swedish Orphan Biovitrum şirketinin kazançları yıllık ortalama -4.9% oranında azalırken, Biotechs sektörünün kazançları yıllık 13.4% oranında artan oldu. Gelirler yıllık ortalama 12.3% oranında artan oldu. Swedish Orphan Biovitrum şirketinin öz sermaye getirisi 5.9% olup, net marjı 9% dir.

Anahtar bilgiler

-4.9%

Kazanç büyüme oranı

-6.9%

EPS büyüme oranı

Biotechs Sektör Büyümesi	0.7%
Gelir büyüme oranı	12.3%
Özkaynak getirisi	5.9%
Net Marj	9.0%
Sonraki Kazanç Güncellemesi	24 Oct 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Earnings Beat: Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jul 19

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Jun 24

Here's Why Shareholders May Consider Paying Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) CEO A Little More

May 08

Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Apr 27

Investors Still Waiting For A Pull Back In Swedish Orphan Biovitrum AB (publ) (STO:SOBI)

Apr 24

Swedish Orphan Biovitrum AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Apr 06

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Mar 05

Swedish Orphan Biovitrum's (STO:SOBI) Weak Earnings May Only Reveal A Part Of The Whole Picture

Feb 15

Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Earnings Haven't Escaped The Attention Of Investors

Jan 17

These 4 Measures Indicate That Swedish Orphan Biovitrum (STO:SOBI) Is Using Debt Reasonably Well

Dec 27

Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Sep 28

Is Swedish Orphan Biovitrum (STO:SOBI) Using Too Much Debt?

Jun 26

Swedish Orphan Biovitrum (STO:SOBI) Has A Somewhat Strained Balance Sheet

Mar 28

Gelir ve Gider Dağılımı

Swedish Orphan Biovitrum nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

OM:SOBI Gelir, gider ve kazançlar (SEK Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	23,710	2,145	10,609	3,257
31 Mar 24	23,140	2,142	10,201	2,903
31 Dec 23	22,123	2,409	9,773	2,743
30 Sep 23	21,270	2,769	8,951	2,594
30 Jun 23	20,100	3,125	8,202	2,358
31 Mar 23	19,104	3,162	7,859	2,371
31 Dec 22	18,790	2,638	7,637	2,252
30 Sep 22	17,696	2,493	7,340	2,156
30 Jun 22	17,458	2,516	7,077	2,116
31 Mar 22	16,793	2,526	6,667	2,042
31 Dec 21	15,529	2,679	6,294	1,987
30 Sep 21	15,214	2,940	6,022	1,926
30 Jun 21	14,424	2,744	5,868	1,845
31 Mar 21	14,283	2,759	5,876	1,706
31 Dec 20	15,261	3,245	5,981	1,594
30 Sep 20	15,570	3,103	5,894	1,418
30 Jun 20	15,530	3,367	5,615	1,306
31 Mar 20	15,622	3,583	5,358	1,475
31 Dec 19	14,248	3,304	4,807	1,448
30 Sep 19	11,929	2,539	4,093	1,466
30 Jun 19	11,313	2,620	3,578	1,460
31 Mar 19	10,440	2,806	2,952	1,189
31 Dec 18	9,139	2,418	2,511	1,090
30 Sep 18	8,443	2,181	2,335	991
30 Jun 18	7,729	1,881	2,206	918
31 Mar 18	7,079	1,462	2,136	923
31 Dec 17	6,511	1,149	2,084	908
30 Sep 17	5,927	865	2,018	937
30 Jun 17	5,497	677	1,963	902
31 Mar 17	5,327	703	1,861	858
31 Dec 16	5,204	802	1,776	778
30 Sep 16	4,727	716	1,633	654
30 Jun 16	4,341	585	1,539	595
31 Mar 16	3,636	291	1,463	519
31 Dec 15	3,228	65	1,345	513
30 Sep 15	3,119	59	1,263	528
30 Jun 15	3,000	108	1,177	499
31 Mar 15	2,899	136	1,094	505
31 Dec 14	2,607	-268	1,031	500
30 Sep 14	2,513	-263	1,007	453
30 Jun 14	2,364	-373	971	475
31 Mar 14	2,221	-410	933	463
31 Dec 13	2,177	-93	896	456

Kaliteli Kazançlar: SOBI yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: SOBI 'nin mevcut net kar marjları (9%) geçen yılın (15.5%) değerinden daha düşüktür.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: SOBI şirketinin kazançları son 5 yılda yılda 4.9% oranında azaldı.

Büyüme Hızlandırma: SOBI 'in son bir yıldır negatif kazanç büyümesi oldu, bu nedenle 5 yıllık ortalamasıyla karşılaştırılamaz.

Kazançlar vs. Sektör: SOBI geçtiğimiz yıl negatif kazanç büyümesine ( -31.4% ) sahipti ve bu da onu Biotechs sektör ortalamasıyla ( -18.6% ) karşılaştırmayı zorlaştırıyordu.

Özkaynak Getirisi

Yüksek ROE: SOBI 'nin Özsermaye Getirisi ( 5.9% ) düşük olarak değerlendiriliyor.

Swedish Orphan Biovitrum Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 1/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Swedish Orphan Biovitrum AB (publ) to Report Q2, 2025 Results on Jul 16, 2025

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Swedish Orphan Biovitrum AB (publ) to Report Q4, 2024 Results on Feb 05, 2025

First quarter 2024 earnings released: EPS: kr2.35 (vs kr3.60 in 1Q 2023)

Full year 2023 earnings: EPS misses analyst expectations

Swedish Orphan Biovitrum AB (publ) to Report Fiscal Year 2023 Final Results on Apr 02, 2024

Recent updates

Swedish Orphan Biovitrum AB (publ) to Report Q2, 2025 Results on Jul 16, 2025

General Counsel & Head of Legal Affairs recently sold kr27m worth of stock

Investor sentiment improves as stock rises 15%

Sobi and Apellis Announce Positive Topline Results from Phase 3 Valiant Study of Pegcetacoplan in C3G and Primary IC-MPGN

CEO & President recently sold kr29m worth of stock

Earnings Beat: Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Sobi Announces the Publication of Full Results from the Phase 3 XTEND- Kids Study in Thenew England Journal of Medicine Confirming the Safety and Efficacy Profile of Altuvoct

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates increase by 21%

Swedish Orphan Biovitrum AB (publ) Updates Earnings Guidance for the Year 2024

Sobi Initiates Rolling Biologics License Application to FDA for SEL-212 for the Potential Treatment of Chronic Refractory Gout

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

European Commission Grants Sobi® Marketing Authorisation for Altuvoct™ for Treatment of Haemophilia A

Head of North America recently sold kr37m worth of stock

CEO & President recently sold kr30m worth of stock

Swedish Orphan Biovitrum AB (publ) Elects Zlatko Rihter as New Board Member

Here's Why Shareholders May Consider Paying Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) CEO A Little More

Swedish Orphan Biovitrum AB (Publ) Provides Earnings Guidance for 2024

Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Swedish Orphan Biovitrum AB (publ) to Report Q4, 2024 Results on Feb 05, 2025

First quarter 2024 earnings released: EPS: kr2.35 (vs kr3.60 in 1Q 2023)

Investors Still Waiting For A Pull Back In Swedish Orphan Biovitrum AB (publ) (STO:SOBI)

Swedish Orphan Biovitrum AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Full year 2023 earnings: EPS misses analyst expectations

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Swedish Orphan Biovitrum AB (publ) to Report Fiscal Year 2023 Final Results on Apr 02, 2024

Head of Technical Operations recently sold kr5.7m worth of stock

Swedish Orphan Biovitrum's (STO:SOBI) Weak Earnings May Only Reveal A Part Of The Whole Picture

Full year 2023 earnings: EPS misses analyst expectations

Swedish Orphan Biovitrum AB (Publ) Provides Revenue Guidance for the Year 2024

Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Earnings Haven't Escaped The Attention Of Investors

Swedish Orphan Biovitrum AB (Publ) Announces Resignation of Bo Jesper Hansen as Chairman of the Board and Board Member

Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Senior Scientific & Medical Advisor recently sold kr16m worth of stock

Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 14, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G

Sobi Appoints Lydia Abad-Franch as Head of R&D and Chief Medical Officer

Sanofi S.A. and Sobi Announce Once-Weekly ALTUVIIIO Approved in Japan as A New Class of Factor VIII Therapy for Hemophilia A

Independent Director recently bought kr439k worth of stock

New minor risk - Shareholder dilution

Swedish Orphan Biovitrum AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 6.023593 billion.

Independent Director recently bought kr439k worth of stock

Swedish Orphan Biovitrum AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

New major risk - Financial position

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates increase by 12%

Is Swedish Orphan Biovitrum (STO:SOBI) Using Too Much Debt?

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) completed the acquisition of CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders.

Head of International recently sold kr386k worth of stock

European Medicines Agency Validates Sobi's Marketing Authorisation Application for Efanesoctocog Alfa for Treatment of Haemophilia A

Independent Chairman recently bought kr11m worth of stock

Less than half of directors are independent

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) entered into a definitive agreement and plan of merger to acquire CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders for $1.2 billion.

Swedish Orphan Biovitrum AB (Publ) Approves Election of Christophe Bourdon and Anders Ullman as Members of the Board

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Head of Europe recently sold kr15m worth of stock

CEO & President recently sold kr24m worth of stock

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Swedish Orphan Biovitrum AB (Publ) Provides Earnings Guidance for 2023

Swedish Orphan Biovitrum AB (Publ) Announces Executive Changes

Is Swedish Orphan Biovitrum AB (publ) (STO:SOBI) Trading At A 30% Discount?

These 4 Measures Indicate That Swedish Orphan Biovitrum (STO:SOBI) Is Using Debt Reasonably Well

ADC Therapeutics SA and Swedish Orphan Biovitrum AB Announce the European Commission Approval of Zynlonta® (Loncastuximab Tesirine)

Sobi North America, the North American Affiliate of Swedish Orphan Biovitrum AB Announces That U.S. Food and Drug Administration Issues Emergency Use Authorization for Kineret® (Anakinra) for the Treatment of Covid-19-Related Pneumonia

Swedish Orphan Biovitrum AB (Publ)'s Chairman of the Board Håkan Björklund Will Not Be Available for Re-Election At the Annual General Meeting 2023

Swedish Orphan Biovitrum AB (publ) to Report Q3, 2023 Results on Oct 26, 2023

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations